Table 6.
Genotype | Stratified factors | Positive OR (95% CI)a | P-valueb | Prior probability
|
|||
---|---|---|---|---|---|---|---|
0.25 | 0.1 | 0.01 | 0.001 | ||||
rs217727 | |||||||
CT/CC | All subjects | 1.25 (1.03–1.51) | 0.023 | 0.06 | 0.161 | 0.678 | 0.955 |
TT/CC | All subjects | 1.56 (1.15–2.09) | 0.004 | 0.021 | 0.061 | 0.419 | 0.879 |
CT + TT/CC | All subjects | 1.31 (1.09–1.57) | 0.004 | 0.007 | 0.022 | 0.197 | 0.712 |
ER+ | 1.34 (1.09–1.64) | 0.004 | 0.015 | 0.045 | 0.341 | 0.84 | |
HER2− | 1.4 (1.14–1.71) | 0.001 | 0.004 | 0.012 | 0.114 | 0.565 | |
HR+ HER2− | 1.45 (1.16–1.81) | 0.001 | 0.005 | 0.015 | 0.141 | 0.623 |
Notes:
Crude OR;
logistic regression analysis for genotype-frequency distributions.
Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio.